Literature DB >> 2146234

Secondary treatment of advanced cancer of the prostate with Zoladex.

P Klarskov1, F Lund, S E Petersen.   

Abstract

Twelve patients with advanced prostatic carcinoma and relapse following previous hormone manipulation therapy were treated with Zoladex-depot every 4 weeks. The treatment was well tolerated and the endocrine response was satisfactory. However, no clinically important improvement was obtained.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2146234     DOI： 10.1007/bf02549796

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  5 in total

1.  The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.

Authors:  C J Beacock; A C Buck; R Zwinck; W B Peeling; R W Rees; A Turkes; K Walker; K Griffiths
Journal:  Br J Urol       Date:  1987-05

2.  Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.

Authors:  J M Allen; J P O'Shea; K Mashiter; G Williams; S R Bloom
Journal:  Br Med J (Clin Res Ed)       Date:  1983-05-21

3.  Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer.

Authors:  D Kerle; G Williams; H Ware; A Doble; J Allen; S R Bloom
Journal:  Br J Urol       Date:  1984-10

4.  Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).

Authors:  K J Walker; A O Turkes; A Turkes; R Zwink; C Beacock; A C Buck; W B Peeling; K Griffiths
Journal:  J Endocrinol       Date:  1984-11       Impact factor: 4.286

5.  LHRH analogue as a depot preparation (Zoladex) in the treatment of advanced carcinoma of the prostate followed by orchiectomy as a second line therapy--a phase II study.

Authors:  P Iversen; C Rose; J G Stage; H G Iversen; R I Hansen; V Hvidt; P Mogensen; T Pedersen; J B Hansen
Journal:  Scand J Urol Nephrol       Date:  1989
  5 in total
  1 in total

Review 1.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.

Authors:  R N Brogden; D Faulds
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.